Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.

Painter NA, Morello CM, Singh RF, McBane SE.

J Am Board Fam Med. 2013 Mar-Apr;26(2):203-10. doi: 10.3122/jabfm.2013.02.120174.

2.
3.

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

Ryan GJ, Moniri NH, Smiley DD.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Review.

PMID:
23784159
4.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
5.

Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.

Minze MG, Klein MS, Jernigan MJ, Wise SL, Frugé K.

Pharmacotherapy. 2013 Jun;33(6):627-38. doi: 10.1002/phar.1240. Epub 2013 Apr 1. Review.

PMID:
23553357
6.

[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].

Lecube A, Bueno M, Suárez X.

Med Clin (Barc). 2014 Sep;143 Suppl 2:23-7. doi: 10.1016/S0025-7753(14)70105-8. Epub 2014 Oct 15. Review. Spanish.

PMID:
25437462
8.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
9.

[Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].

Reuter H, Erdmann E.

Dtsch Med Wochenschr. 2007 Mar 16;132(11):571-4. Review. German.

PMID:
17342635
10.

Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.

King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G.

Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR.

PMID:
23186975
11.

The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.

Guo XH.

Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11. Review.

PMID:
26439329
12.

[Glucagon-like peptide 1 (GLP-1)].

Parhofer KG.

MMW Fortschr Med. 2007 Jun 21;149(25-26):41-3. German.

PMID:
17713050
13.
14.

Exenatide extended-release: a review of its use in type 2 diabetes mellitus.

Scott LJ.

Drugs. 2012 Aug 20;72(12):1679-707. doi: 10.2165/11209750-000000000-00000. Review.

PMID:
22867046
15.

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

Alves C, Batel-Marques F, Macedo AF.

Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.

PMID:
23010561
16.

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

Madsbad S.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. doi: 10.1016/j.beem.2009.03.008. Review.

PMID:
19748064
17.

Exenatide: new drug. Type 2 diabetes for some overweight patients.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):228-31.

PMID:
18087791
18.
19.

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

Jespersen MJ, Knop FK, Christensen M.

Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):17-29. doi: 10.1517/17425255.2013.731394. Epub 2012 Oct 24. Review.

PMID:
23094590
20.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300. Epub 2010 Dec 6.

PMID:
21138825

Supplemental Content

Support Center